SEATTLE, WA--(MARKET WIRE)--Aug 6, 2007 -- Targeted Genetics Corporation (NasdaqCM:TGEN - News) responded to an article in today’s Washington Post with respect to its development program of tgAAC94, an investigational therapy for the treatment of inflammatory arthritis. The Company believes that it is unfortunate that the article seems designed to agitate as opposed to inform. The incident central to the article currently is being assessed by the Company and the FDA, and the Company believes that it would be premature as well as irresponsible to draw any conclusions prior to the completion of that investigation.
